Day: 3 September 2018

Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral...

Clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic combination among patients with multiple myeloma (MM),...